Retatrutide 20mg

Description

Retatrutide 20 mg provides an expanded quantity of this triple-receptor agonist peptide, supporting mid-scale research programs that require additional material for dose-response evaluations, mechanism-of-action studies, and comparative pharmacology experiments.

Retatrutide is designed to activate glucose-dependent insulinotropic polypeptide, commonly known as GIP, glucagon-like peptide-1, commonly known as GLP-1, and glucagon receptors. This triple-agonist profile distinguishes it from conventional single and dual-receptor compounds and makes it a valuable research tool for investigating integrated metabolic signaling and G protein-coupled receptor biology.

In cell-based functional assays, the 20 mg presentation provides sufficient material for constructing complete efficacy and potency curves across multiple receptor-expressing cell lines and assay platforms. Researchers may use Retatrutide in radioligand displacement studies, cyclic adenosine monophosphate accumulation assays, receptor-binding evaluations, and bioluminescence resonance energy transfer techniques used to observe real-time receptor activity and conformational changes.

The glucagon receptor component provides an additional research dimension not present in dual-agonist peptides. This allows investigators to examine the combined effects of incretin and glucagon receptor activation and compare triple-receptor signaling with single and dual-receptor models.

The 20 mg format offers a practical balance between experimental capacity and reagent efficiency for developing research programs. Each PEPTEX Labs production lot is subject to quality-control testing, which may include HPLC purity analysis, mass spectrometry verification, amino acid analysis, net-content testing, and endotoxin analysis. Supporting documentation is provided according to the testing completed for each individual batch.

This product is supplied exclusively for qualified laboratory research. It is not intended for human or veterinary use.